NEXT PLAYER CO., LTD. – Trademark Portfolio
Entity Type: 03
NEXT PLAYER CO., LTD. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 7 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 3 trademarks are registered and 4 are pending. Notable registered marks include CANDYLAB, LUCKY CLOVER, and H HEALTH HELPER.
22F, 17, Seobinggo-ro, Yongsan-gu
Seoul
Showing of trademarks Trademarks
Trademark Classifications
NEXT PLAYER CO., LTD.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does NEXT PLAYER CO., LTD. have?
NEXT PLAYER CO., LTD. has 10 U.S. trademarks filed with the USPTO. Of these, 3 registered, 4 pending, 3 abandoned.
What trademark classes does NEXT PLAYER CO., LTD. file in?
NEXT PLAYER CO., LTD. files trademarks across 3 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 35 covers advertising; business management; business administration; office functions.
What are NEXT PLAYER CO., LTD.'s most well-known trademarks?
NEXT PLAYER CO., LTD.'s registered trademark portfolio includes well-known marks such as CANDYLAB, LUCKY CLOVER, and H HEALTH HELPER. These are among 3 currently registered trademarks in the portfolio.
What is NEXT PLAYER CO., LTD.'s trademark registration success rate?
NEXT PLAYER CO., LTD. has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 4 applications are pending review.